
## **Product Data Sheet**

## Brilliant Violet 421<sup>™</sup> anti-human CD154

Catalog # / Size:	2154115 / 25 tests 2154120 / 100 tests	
Clone:	24-31	
Isotype:	: Mouse lgG1, к	
<b>Reactivity:</b>	Human	
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421 <sup>™</sup> under optimal conditions. The solution is free of unconjugated Brilliant Violet 421 <sup>™</sup> and unconjugated antibody.	
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	P
Concentration:	Lot-specific	p s E h



PMA+ionomycin-stimulated human peripheral blood lymphocytes were stained with CD154 (clone 24-31) Brilliant Violet 421<sup>™</sup> (filled histogram) or mouse IgG1, κ Brilliant Violet 421<sup>™</sup> isotype control (open histogram).

## **Applications:**

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is $\leq 5$ microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
	Brilliant Violet 421 <sup>™</sup> excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421 <sup>™</sup> is a trademark of Sirigen Group Ltd.
	This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Application Notes:	Additional reported applications (for the relevant formats) include: immunofluorescence microscopy <sup>1,3</sup> and blocking of T cell-dependent B cell differentiation <sup>1,2,4,5</sup> . The LEAF <sup><math>m</math></sup> purified antibody (Endotoxin <0.1 EU/µg, Azide- Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 310812). For highly sensitive assays, we recommend Ultra-LEAF <sup><math>m</math></sup> purified antibody (Cat. No. 310828) with a lower endotoxin limit than standard LEAF <sup><math>m</math></sup> purified antibodies (Endotoxin <0.01 EU/microg).
Application References:	<ol> <li>Brams P, <i>et al.</i> 2001. <i>Int. Immunopharmacol.</i> 1:277. (Block, IF)</li> <li>Rushworth SA, <i>et al.</i> 2002. <i>Transplantation</i> 73:635. (Block)</li> <li>Berner B, <i>et al.</i> 2000. <i>Ann. Rheum. Dis.</i> 59:190. (IF)</li> <li>Nordström T, <i>et al.</i> 2006. <i>J. Leukocyte Biol.</i> 79:319. (Block)</li> </ol>

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

5. Zhang AL, et al. 2007. Blood doi: 10.1182/blood-2007-02-076364. (Block) PubMed

- 6. Kuchen S, et al. 2007. J. Immunol. 179:5886.
- 7. Matus-Nicodermos R, et al. 2011. J. Immunol. 186:2164. PubMed

Description:	CD154 (CD40 ligand) is also known as CD40L, gp39, TRAP and T-BAM. CD40 ligand is a 32-39 kD type II transmembrane glycoprotein. It is a member of the			
	TNF superfamily and is expressed on activated T cells. It has been reported to be important for B cell costimulation following binding of its receptor, CD40.			
	Additionally, binding of CD40L to CD40 on B cells promotes the secretion of			
	immunoglobulin and Ig isotype switching. CD40L is also involved in the regulation of cytokine production by T cells.			

Antigen	<ol> <li>Najafian N,</li> </ol>	et al. 2003. Expert Opl	n. Biol. Ther. 3:227.
---------	---------------------------------	-------------------------	-----------------------

- References:
- 2. Racke M, *et al.* 2002. *Expert Opin. Ther. Targets.* 6:275. 3. Ford G, *et al.* 1999. *J. Immunol.* 162:4037.